Home > Cardiology > Cardiovascular, kidney benefits consistent across SGLT2 inhibitors

Cardiovascular, kidney benefits consistent across SGLT2 inhibitors

JAMA Cardiology
Reuters Health - 19/10/2020 - Sodium-glucose transporter 2 (SGLT2) inhibitors lower the risk of major adverse cardiovascular (CV) outcomes in people with type-2 diabetes, according to a new meta-analysis including the four available drugs in the class. Outcomes were heterogeneous for CV death, and most consistent for hospitalization for heart failure (HHF) and kidney outcomes, Dr. Darren K. McGuire of the University of Texas Southwestern Medical Center in Dallas and colleagues found. "The present results augment the growing evidence base that SGLT2 inhibitors in general are associated with favorable CV and kidney outcomes; in addition, the present study refines understanding of important differences in outcomes associated with drugs within the class," Dr. McGuire and colleagues write in JAMA Cardiology. The authors analyzed six randomized controlled trials of SGLT2 inhibitors including nearly 47,000 patients with type-2 diabetes, two-thirds of whom had athero...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on